Bioventus (BVS) Q1 2026 Earnings
How Did BVS Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +0.73%.
Did BVS Beat Earnings? Q1 2026 Results
Yes. Bioventus reported Q1 2026 earnings of $0.15 a share on May 6, 2026, beating the $0.07 consensus estimate by 120.6%. Revenue was $132.1M against a $129.9M estimate.
Bioventus Inc. posted a standout first quarter of 2026, with adjusted EPS of $0.15 beating the $0.07 consensus estimate by 120.59% and revenue of $132.09 million edging past the $129.90 million forecast by 1.69%, reflecting 6.6% year-over-year growth. The most material driver of the upside was a broad-based contribution across all three business segments, headlined by a favorable $4.20 million rebate adjustment in Pain Treatments and sustained U.S. demand in Surgical Solutions, where Bone Graft Substitutes and Ultrasonics each gained traction. Profitability improved sharply, with Adjusted EBITDA expanding 24% to $23.91 million and Non-GAAP operating margin widening to 15.4% from 14.3% a year earlier. Notably, operating cash flow swung to $8.93 million from an outflow of $19.33 million in the prior-year period, allowing Bioventus to make a discretionary $22.00 million term loan prepayment in late March. Management responded to the momentum by raising full-year Adjusted EPS guidance to $0.75–$0.79 and Cash from Operations guidance to $84.00–$89.00 million, while reaffirming net sales guidance of $600.00–$610.00 million for 2026.
- Favorable $4.2 million rebate benefit from billing process change by a third-party private insurer in Pain Treatments
- Higher U.S. demand for Bone Graft Substitutes and Ultrasonics in Surgical Solutions
- Continued commercial effectiveness and sales force execution with EXOGEN Bone Stimulation System
- Strong international growth of 17.1% driven by Ultrasonics and HA therapies for knee osteoarthritis
- Net interest expense declined to $4.3 million from $7.5 million due to debt reduction
- Non-GAAP gross margin expanded to 76.4% from 75.3%
“Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and operational priorities.”
Bioventus CEO, on the earnings call
What Was Bioventus's Outlook in Q1 2026?
Bioventus raised full-year 2026 guidance for Adjusted EPS to $0.75–$0.79 (up $0.02 from prior guidance) and Cash from Operations to $84 million–$89 million (up $2 million), driven by accelerated cash flow and faster-than-anticipated debt repayment. The company reaffirmed its 2026 net sales guidance of $600 million to $610 million, reflecting approximately 6%–7% growth.
BVS YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $132.1M | $123.9M | +6.6% |
| Gross Profit | $90.8M | $83.1M | +9.3% |
| Operating Income | $8.4M | $4.9M | +72.9% |
| Net Income | $3.1M | $978,777 | +218.1% |
BVS Revenue by Segment
BVS Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.